Light-adjustable IOL may allow for fine-tuning after implantation


Lisbon, Portugal—Accurate adjustment of the new Light Adjustable Intraocular Lens (LAL) (Calhoun Vision) after implantation is possible using new digital light delivery systems and may eliminate the need for explantation of the IOL because of incorrect lens power after cataract surgery, reported Nick Mamalis, MD, at the annual meeting of the European Society of Cataract and Refractive Surgeons.

What makes adjustment of the LAL possible is the new Digital Light Delivery Device, which was designed and manufactured by Carl Zeiss Meditec AG. It allows customization of the lens correction, precise correction of astigmatism, and even a possible wavefront pattern of light delivery. The instrument is a modified slit-lamp that has a digital chip with 1.3 million microscopic mirrors. The device is installed and serviced by Carl Zeiss Meditec; the system and software are sold by Calhoun Vision.

"The Light Delivery Device is mounted on a conventional slit lamp. The refractive error and desired refractive outcome are entered on the color console and irradiation is activated using either a foot pedal or joy stick," Dr. Mamalis explained.

"Accurate IOL power adjustments were possible using the new Digital Light Delivery system in terms of myopic, hyperopic, and astigmatic correction in clinical studies performed by Dr. Arturo Chayet in Mexico," Dr. Mamalis reported (Figure 1).

How the technology works

Dr. Mamalis described how the LAL is fine-tuned using the Light Delivery Device after implantation of the IOL.

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.